{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:17Z","timestamp":1792001897215,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020537","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtho.2025.08.011","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:59:27Z","timestamp":1760893167000},"page":"1829-1842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Yeong Hak","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myoung","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongryull","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong Jeong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Ho","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Soo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehhoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.08.011_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorc.2025.100024","article-title":"Thymic epithelial tumors: what\u2019s new and what\u2019s next?","author":"Imbimbo","year":"2025","journal-title":"ESMO Rare Cancers"},{"key":"10.1016\/j.jtho.2025.08.011_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5090\/jcs.21.124","article-title":"An overview of surgical treatment of thymic epithelial tumors in Korea: a retrospective multicenter analysis","volume":"55","author":"Lee","year":"2022","journal-title":"J Chest Surg"},{"key":"10.1016\/j.jtho.2025.08.011_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.athoracsur.2012.09.006","article-title":"Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients","volume":"95","author":"Weksler","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.08.011_bib5","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"ESMO Guidelines Committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jtho.2022.08.007","article-title":"Surgical, radiation, and systemic treatments of patients with thymic epithelial tumors: a clinical practice guideline","volume":"17","author":"Falkson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtcvs.2013.08.061","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2025.08.011_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.athoracsur.2007.08.051","article-title":"Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors","volume":"85","author":"Wright","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2025.08.011_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lungcan.2016.01.008","article-title":"Induction therapy followed by surgical resection in Stage-III thimic epithelial tumors: long-term results from a multicentre analysis of 108 cases","volume":"93","author":"Cardillo","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib11","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.08.011_bib12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.08.011_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.08.011_bib14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.08.011_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002248","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?","volume":"9","author":"Ahern","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO-24-02355","article-title":"Rationale for investigation of neoadjuvant chemoimmunotherapy before chemoradiation in unresectable Stage III non\u2013small cell lung cancer","volume":"43","author":"Thawani","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","article-title":"Current status of immune checkpoint inhibition in early-stage NSCLC","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib19","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label Phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib24","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.08.011_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib27","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.34678","article-title":"Understanding the landscape of immunotherapy in thymic epithelial tumors","volume":"129","author":"Maniar","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2025.08.011_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.08.011_bib30","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.21037\/jtd-2019-thym-10","article-title":"Autoimmune disorders and paraneoplastic syndromes in thymoma","volume":"12","author":"Blum","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2025.08.011_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425010159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425010159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:23:08Z","timestamp":1765498988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425010159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1556086425010159"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.08.011","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Pembrolizumab for Locally Advanced Thymic Epithelial Tumors: A Single-Arm, Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}